601 GENOME WAY, HUNTSVILLE, AL
Certificate of Elimination Filed for Series A Preferred Stock
Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson’s Disease and Advances to Cohort 2
Serina Therapeutics Enters $25 Million Common Stock Purchase Agreement
Reports Second Quarter 2026 Financial Results and Provides Business Updates
Appoints Farrell Simon to its Board of Directors
Material disclosure
Reports First Quarter 2026 Financial Results and Provides Business Updates
Q2
Q1
Amended Annual Report
FY 2025
Q3
FY 2024
Effectiveness Notice
S-1
Registration Statement for Securities to be Offered to Employees
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Contested Proxy Solicitation Materials
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Definitive Revised Proxy Statement
Correspondence
Submission Upload